420 with CNW — Researchers Explore Combining Psilocybin, Cannabinoids in New Therapeutic Formulations
The convergence of cannabinoids and psilocybin in a unified formulation to address physical and psychological well-being has moved closer to realization as highlighted in a patent filed by a prominent cannabinoid laboratory called CaaMTech. Situated in Issaquah, Washington, just under 20 miles southeast of Seattle, CaaMTech is conducting an analysis of the mutual interactions between these two compounds and the specific outcomes they can yield in terms of physical and mental health. Presently, the company’s refined psilocybin-cannabinoid formulation is still in the early stages of development. This patent progress comes at a time when the availability of genetic information on…